Biological Psychiatry
Volume 61, Issue 5 , Pages 582-590 , 1 March 2007

Aripiprazole Blocks Reinstatement of Cocaine Seeking in an Animal Model of Relapse

  • Matthew W. Feltenstein

      Affiliations

    • Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina
    • ,
  • C. Anthony Altar

      Affiliations

    • Psychiatric Genomics, Inc., Gaithersburg, Maryland.
    • ,
  • Ronald E. See

      Affiliations

    • Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina
    • Corresponding Author InformationAddress reprint requests to Dr. Ronald E. See, Department of Neurosciences, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425

Received 11 January 2006 ,Revised 6 April 2006 ,Accepted 6 April 2006.

References 

  1. Assie MB, Ravailhe V, Faucillon V, Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: Frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther. 2005;315:265–272
  2. Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. J Clin Psychopharmacol. 2005;25:363–366
  3. Berglind WJ, Case JM, Parker MP, Fuchs RA, See RE. Dopamine D1 or D2 receptor antagonism within the basolateral amygdala differentially alters the acquisition of cocaine-cue associations necessary for cue-induced reinstatement of cocaine-seeking. Neuroscience. 2006;137:699–706
  4. Bowles TM, Levin GM. Aripiprazole: A new atypical antipsychotic drug. Ann Pharmacother. 2003;37:687–694
  5. Brown ES, Jeffress J, Liggin JD, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005;66:756–760
  6. Cervo L, Carnovali F, Stark JA, Mennini T. Cocaine-seeking behavior in response to drug-associated stimuli in rats: Involvement of D3 and D2 dopamine receptors. Neuropsychopharmacology. 2003;28:1150–1159
  7. Childress AR, Hole AV, Ehrman RN, Robbins SJ, McLellan AT, O’Brien CP. Cue reactivity and cue reactivity interventions in drug dependence. NIDA Res Monogr. 1993;137:73–95
  8. Childress AR, O’Brien CP. Dopamine receptor partial agonists could address the duality of cocaine craving. Trends Pharmacol Sci. 2000;21:6–9
  9. Cornish JL, Duffy P, Kalivas PW. A role for nucleus accumbens glutamate transmission in the relapse to cocaine-seeking behavior. Neuroscience. 1999;93:1359–1367
  10. Dackis CA, O’Brien CP. Cocaine dependence: A disease of the brain’s reward centers. J Subst Abuse Treat. 2001;21:111–117
  11. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004;10:317–336
  12. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192–208
  13. De La Garza R, Newton TF, Kalechstein AD. Risperidone diminishes cocaine-induced craving. Psychopharmacology. 2005;178:347–350(Berl)
  14. DeLeon A, Patel NC, Crismon ML. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649–666
  15. Duarte C, Lefebvre C, Chaperon F, Hamon M, Thiebot MH. Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats. Neuropsychopharmacology. 2003;28:1903–1915
  16. Filip M. Role of serotonin (5-HT)2 receptors in cocaine self-administration and seeking behavior in rats. Pharmacol Rep. 2005;57:35–46
  17. Fletcher PJ, Grottick AJ, Higgins GA. Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology. 2002;27:576–586
  18. Fuchs RA, Evans KA, Ledford CC, Parker MP, Case JM, Mehta RH, et al. The role of the dorsomedial prefrontal cortex, basolateral amygdala, and dorsal hippocampus in contextual reinstatement of cocaine seeking in rats. Neuropsychopharmacology. 2005;30:296–309
  19. Fuchs RA, Evans KA, Parker MC, See RE. Differential involvement of the core and shell subregions of the nucleus accumbens in conditioned cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology. 2004;176:459–465(Berl)
  20. Fuchs RA, Evans KA, Parker MP, See RE. Differential involvement of orbitofrontal cortex subregions in conditioned cue-induced and cocaine-primed reinstatement of cocaine seeking in rats. J Neurosci. 2004;24:6600–6610
  21. Gal K, Gyertyan I. Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats. Brain Res Bull. 2003;61:595–601
  22. Gal K, Gyertyan I. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend. 2006;81:63–70
  23. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: Occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60:974–977
  24. Gyertyan I, Gal K. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference. Neuroreport. 2003;14:93–98
  25. Heidbreder C. Novel pharmacotherapeutic targets for the management of drug addiction. Eur J Pharmacol. 2005;526:101–112
  26. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 2004;18:375–383
  27. Jaffe JH, Cascella NG, Kumor KM, Sherer MA. Cocaine-induced cocaine craving. Psychopharmacology. 1989;97:59–64
  28. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137–140
  29. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763–771
  30. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6:325–337
  31. Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651–1658
  32. Khroyan TV, Barrett-Larimore RL, Rowlett JK, Spealman RD. Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: Effects of selective antagonists and agonists. J Pharmacol Exp Ther. 2000;294:680–687
  33. Kippin TE, Fuchs RA, Mehta RH, Case JM, Parker MP, Bimonte-Nelson HA, et al. Potentiation of cocaine-primed reinstatement of drug seeking in female rats during estrus. Psychopharmacology. 2005;182:245–252(Berl)
  34. Kleven MS, Barret-Grevoz C, Slot LB, Newman-Tancredi A. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology. 2005;49:135–143
  35. Kosten TR, George TP, Kosten TA. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs. 2002;11:491–499
  36. Kruzich PJ, See RE. Differential contributions of the basolateral and central amygdala in the acquisition and expression of conditioned relapse to cocaine-seeking behavior. J Neurosci. 2001;21:RC155
  37. Langlois X, te Riele P, Ashton D. In vivo receptor occupancy profile of aripiprazole in rat brain. Soc Neurosci Abstracts. 2005;444:3
  38. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC–14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999;20:612–627
  39. Ledford CC, Fuchs RA, See RE. Potentiated reinstatement of cocaine-seeking behavior following D-amphetamine infusion into the basolateral amygdala. Neuropsychopharmacology. 2003;28:1721–1729
  40. Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol. 2004;493:75–83
  41. Lieberman JA. Dopamine partial agonists: A new class of antipsychotic. CNS Drugs. 2004;18:251–267
  42. Lile JA, Stoops WW, Vansickel AR, Glaser PE, Hays LR, Rush CR. Aripiprazole Attenuates the discriminative-stimulus and subject-rated effects of d-amphetamine in humans. Neuropsychopharmacology. 2005;30:2103–2114
  43. Longo LP. Olanzapine for cocaine craving and relapse prevention in 2 patients. J Clin Psychiatry. 2002;63:595–596
  44. Meil WM, See RE. Lesions of the basolateral amygdala abolish the ability of drug associated cues to reinstate responding during withdrawal from self-administered cocaine. Behav Brain Res. 1997;87:139–148
  45. Mutschler NH, Bergman J. Effects of chronic administration of the D1 receptor partial agonist SKF 77434 on cocaine self-administration in rhesus monkeys. Psychopharmacology. 2002;160:362–370(Berl)
  46. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S (in press): Dissociation between In vivo occupancy and functional antagonism of dopamine D(2) receptors: Comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology.
  47. Neisewander JL, Baker DA, Fuchs RA, Tran-Nguyen LT, Palmer A, Marshall JF. Fos protein expression and cocaine-seeking behavior in rats after exposure to a cocaine self-administration environment. J Neurosci. 2000;20:798–805
  48. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1–93
  49. O’Brien MS, Anthony JC. Risk of becoming cocaine dependent: Epidemiological estimates for the United States, 2000–2001. Neuropsychopharmacology. 2005;30:1006–1018
  50. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature. 1999;400:371–375
  51. Platt DM, Rodefer JS, Rowlett JK, Spealman RD. Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys. Psychopharmacology. 2003;166:298–305(Berl)
  52. Platt DM, Rowlett JK, Spealman RD. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology. 2002;163:265–282(Berl)
  53. Pulvirenti L, Balducci C, Piercy M, Koob GF. Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat. J Pharmacol Exp Ther. 1998;286:1231–1238
  54. Roberts DC, Vickers G. Atypical neuroleptics increase self-administration of cocaine: An evaluation of a behavioural screen for antipsychotic activity. Psychopharmacology. 1984;82:135–139(Berl)
  55. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: An incentive-sensitization view. Addiction. 2000;95(suppl 2):S91–S117
  56. See RE, Fuchs RA, Ledford CC, McLaughlin J. Drug addiction, relapse, and the amygdala. Ann N Y Acad Sci. 2003;985:294–307
  57. See RE, Kruzich PJ, Grimm JW. Dopamine, but not glutamate, receptor blockade in the basolateral amygdala attenuates conditioned reward in a rat model of relapse to cocaine-seeking behavior. Psychopharmacology. 2001;154:301–310(Berl)
  58. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J. The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology. 2003;168:3–20(Berl)
  59. Shalev U, Grimm JW, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: A review. Pharmacol Rev. 2002;54:1–42
  60. Sloboda Z. Changing patterns of “drug abuse” in the United States: Connecting findings from macro- and microepidemiologic studies. Subst Use Misuse. 2002;37:1229–1251
  61. Smelson DA, Williams J, Ziedonis D, Sussner BD, Losonczy MF, Engelhart C, et al. A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat. 2004;27:45–49
  62. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: Illustrating their mechanism of action. J Clin Psychiatry. 2001;62:923–924
  63. Stewart J. Pathways to relapse: The neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiatry Neurosci. 2000;25:125–136
  64. Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: The state of the science. Am J Psychiatry. 2005;162:1432–1440
  65. Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26:479–488
  66. Weiss F, Maldonado-Vlaar CS, Parsons LH, Kerr TM, Smith DL, Ben-Shahar O. Control of cocaine-seeking behavior by drug-associated stimuli in rats: Effects on recovery of extinguished operant-responding and extracellular dopamine levels in amygdala and nucleus accumbens. Proc Natl Acad Sci U S A. 2000;97:4321–4326
  67. White FJ, Kalivas PW. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend. 1998;51:141–153
  68. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663–667
  69. Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett. 2005;387:157–161

PII: S0006-3223(06)00484-7

doi: 10.1016/j.biopsych.2006.04.010

Biological Psychiatry
Volume 61, Issue 5 , Pages 582-590 , 1 March 2007

Article Tools

* Image Usage & Resolution